ArticleInternational journal of clinical and experimental pathology2017
Chloroquine sensitizes hepatocellular carcinoma cells to chemotherapy via blocking autophagy and promoting mitochondrial dysfunction.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Simultaneous activation and blockade of autophagy to fight hepatocellular carcinoma.Autophagy reports · 2024Article
- Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches.Cell communication and signaling : CCS · 2023Review
- Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells.Metabolites · 2021Article
- CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin/cisplatin-based combination chemotherapy is the main therapy strategy against hepatocellular carcinoma. However, the cisplatin efficiency is dimmed by the development of drug resistance. Numerous clinical trials are now revealing the promising role of chloroquine, an autophagy inhibitor, as a novel antitumor drug. In the present study, we investigated the regulation by chloroquine on the autophagy and on the sensitivity of hepatocellular carcinoma cells in vitro. Reverse transcription quantitative-polymerase chain reaction (RT-qPCR), western blotting assay, confocal microscopy and flow cytometry (FCM) were used to analyze the autophagy induction by cisplatin in hepatocellular carcinoma HepG2 cells, to examine the chloroquine-mediated autophagy inhibition on the cisplatin-induced apoptosis in HepG2 cells, and to explore the possible involvement of mitochondrial dysfunction in such process. Our results found the autophagy induction by cisplatin in HepG2 cells, basing on such results as increased induction of autophagic vesicles and upregulated conversion of A subunit (LC3-A) to B (LC3-B) subunit of microtubule-associated protein 1 light chain 3. Flow cytometry analysis results demonstrated that the cisplatin-induced apoptosis was aggravated by chloroquine. In addition, the mitochondrial function was downregulated by cisplatin and was deteriorated by chloroquine in HepG2 cells; the mitochondrial membrane potential (MMP) downregulation, the accumulation of reactive oxygen species (ROS) and the mitochondrial superoxide were markedly higher in the chloroquine/cisplatin-treated HepG2 cells than in the cisplatin-treated cells. In conclusion, we concluded that chloroquine sensitized the chemotherapy efficiency of cisplatin against hepatocellular carcinoma HepG2 cells, probably via blocking autophagy and via deteriorating the mitochondrial dysfunction. Chloroquine might be a potential adjuvant agent for overcoming chemotherapy resistance in hepatocellular carcinoma.
Indexed as
Identifiers
31966896PMC6965955W3011444830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.